Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials.
Identifieur interne : 000439 ( Main/Exploration ); précédent : 000438; suivant : 000440Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials.
Auteurs : M. Chalabi [Pays-Bas] ; A. Cardona [Suisse] ; D R Nagarkar [États-Unis] ; A. Dhawahir Scala [Suisse] ; D R Gandara [États-Unis] ; A. Rittmeyer [Allemagne] ; M L Albert [États-Unis] ; T. Powles [Royaume-Uni] ; M. Kok [Pays-Bas] ; F G Herrera [Suisse]Source :
- Annals of oncology : official journal of the European Society for Medical Oncology [ 1569-8041 ] ; 2020.
Abstract
BACKGROUND
Preclinical data have shown that proton pump inhibitors (PPI) can modulate the microbiome, and single-arm studies suggested that antibiotics (ATB) may decrease the efficacy of immune checkpoint inhibitors (ICI), but randomized controlled trial data are lacking. This pooled analysis evaluated the effect of ATB and PPI on outcome in patients randomized between ICI and chemotherapy.
PATIENTS AND METHODS
This retrospective analysis used pooled data from the phase II POPLAR (NCT01903993) and phase III OAK (NCT02008227) trials, which included 1512 patients with previously treated non-small-cell lung cancer (NSCLC) randomly assigned to receive atezolizumab (n = 757) or docetaxel (n = 755). The main objective of this analysis was to assess the impact of ATB and PPI use on overall survival (OS) and progression-free survival (PFS).
RESULTS
A total of 169 (22.3%) patients in the atezolizumab group and 202 (26.8%) in the docetaxel group received ATB, and 234 (30.9%) and 260 (34.4%), respectively, received PPI. Multivariate analysis in all patients revealed that ATB were associated with shorter OS [hazard ratio (HR) 1.20, 95% confidence interval (CI) 1.04-1.39], as was PPI (HR 1.26, 95% CI 1.10-1.44). Within the atezolizumab population, OS was significantly shorter in patients who received ATB (8.5 versus 14.1 months, HR 1.32, 95% CI 1.06-1.63, P = 0.01) or PPI (9.6 versus 14.5 months, HR 1.45, 95% CI 1.20-1.75, P = 0.0001). PPI use was associated with shorter PFS in the atezolizumab population (1.9 versus 2.8 months, HR 1.30, 95% CI 1.10-1.53, P = 0.001). There was no association between ATB and PPI use and PFS or OS within the docetaxel population.
CONCLUSION
In this unplanned analysis from two randomized trials, data suggest that ATB or PPI use in patients with metastatic NSCLC is associated with poor outcome and may influence the efficacy of ICI.
DOI: 10.1016/j.annonc.2020.01.006
PubMed: 32115349
Affiliations:
- Allemagne, Pays-Bas, Royaume-Uni, Suisse, États-Unis
- Angleterre, Canton de Vaud, Grand Londres, Hollande-Septentrionale
- Amsterdam, Lausanne, Londres
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials.</title><author><name sortKey="Chalabi, M" sort="Chalabi, M" uniqKey="Chalabi M" first="M" last="Chalabi">M. Chalabi</name><affiliation wicri:level="3"><nlm:affiliation>Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: m.chalabi@nki.nl.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Cardona, A" sort="Cardona, A" uniqKey="Cardona A" first="A" last="Cardona">A. Cardona</name><affiliation wicri:level="1"><nlm:affiliation>PD Biometrics, F. Hoffmann-La Roche Ltd, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>PD Biometrics, F. Hoffmann-La Roche Ltd, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Nagarkar, D R" sort="Nagarkar, D R" uniqKey="Nagarkar D" first="D R" last="Nagarkar">D R Nagarkar</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Immunology, Genentech, Inc., South San Francisco, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Cancer Immunology, Genentech, Inc., South San Francisco</wicri:regionArea><wicri:noRegion>South San Francisco</wicri:noRegion></affiliation></author><author><name sortKey="Dhawahir Scala, A" sort="Dhawahir Scala, A" uniqKey="Dhawahir Scala A" first="A" last="Dhawahir Scala">A. Dhawahir Scala</name><affiliation wicri:level="1"><nlm:affiliation>PD Biometrics, F. Hoffmann-La Roche Ltd, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>PD Biometrics, F. Hoffmann-La Roche Ltd, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Gandara, D R" sort="Gandara, D R" uniqKey="Gandara D" first="D R" last="Gandara">D R Gandara</name><affiliation wicri:level="1"><nlm:affiliation>Department of Thoracic Oncology, UC Davis Comprehensive Cancer Center, Sacramento, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Thoracic Oncology, UC Davis Comprehensive Cancer Center, Sacramento</wicri:regionArea><wicri:noRegion>Sacramento</wicri:noRegion></affiliation></author><author><name sortKey="Rittmeyer, A" sort="Rittmeyer, A" uniqKey="Rittmeyer A" first="A" last="Rittmeyer">A. Rittmeyer</name><affiliation wicri:level="1"><nlm:affiliation>Department of Thoracic Oncology, Pulmonary Clinic Immenhausen, Immenhausen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Thoracic Oncology, Pulmonary Clinic Immenhausen, Immenhausen</wicri:regionArea><wicri:noRegion>Immenhausen</wicri:noRegion><wicri:noRegion>Immenhausen</wicri:noRegion><wicri:noRegion>Immenhausen</wicri:noRegion></affiliation></author><author><name sortKey="Albert, M L" sort="Albert, M L" uniqKey="Albert M" first="M L" last="Albert">M L Albert</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Immunology, Genentech, Inc., South San Francisco, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Cancer Immunology, Genentech, Inc., South San Francisco</wicri:regionArea><wicri:noRegion>South San Francisco</wicri:noRegion></affiliation></author><author><name sortKey="Powles, T" sort="Powles, T" uniqKey="Powles T" first="T" last="Powles">T. Powles</name><affiliation wicri:level="3"><nlm:affiliation>Centre for Experimental Cancer Medicine, Barts Cancer Institute, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Centre for Experimental Cancer Medicine, Barts Cancer Institute, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Kok, M" sort="Kok, M" uniqKey="Kok M" first="M" last="Kok">M. Kok</name><affiliation wicri:level="3"><nlm:affiliation>Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Tumor Biology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Tumor Biology and Immunology, Netherlands Cancer Institute, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Herrera, F G" sort="Herrera, F G" uniqKey="Herrera F" first="F G" last="Herrera">F G Herrera</name><affiliation wicri:level="3"><nlm:affiliation>Immune Oncology Service, Lausanne University Hospital, Ludwig Institute for Cancer Research, Lausanne, Switzerland. Electronic address: Fernanda.Herrera@chuv.ch.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Immune Oncology Service, Lausanne University Hospital, Ludwig Institute for Cancer Research, Lausanne</wicri:regionArea><placeName><settlement type="city">Lausanne</settlement><region nuts="3" type="region">Canton de Vaud</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32115349</idno><idno type="pmid">32115349</idno><idno type="doi">10.1016/j.annonc.2020.01.006</idno><idno type="wicri:Area/Main/Corpus">000424</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000424</idno><idno type="wicri:Area/Main/Curation">000424</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000424</idno><idno type="wicri:Area/Main/Exploration">000424</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials.</title><author><name sortKey="Chalabi, M" sort="Chalabi, M" uniqKey="Chalabi M" first="M" last="Chalabi">M. Chalabi</name><affiliation wicri:level="3"><nlm:affiliation>Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: m.chalabi@nki.nl.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Cardona, A" sort="Cardona, A" uniqKey="Cardona A" first="A" last="Cardona">A. Cardona</name><affiliation wicri:level="1"><nlm:affiliation>PD Biometrics, F. Hoffmann-La Roche Ltd, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>PD Biometrics, F. Hoffmann-La Roche Ltd, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Nagarkar, D R" sort="Nagarkar, D R" uniqKey="Nagarkar D" first="D R" last="Nagarkar">D R Nagarkar</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Immunology, Genentech, Inc., South San Francisco, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Cancer Immunology, Genentech, Inc., South San Francisco</wicri:regionArea><wicri:noRegion>South San Francisco</wicri:noRegion></affiliation></author><author><name sortKey="Dhawahir Scala, A" sort="Dhawahir Scala, A" uniqKey="Dhawahir Scala A" first="A" last="Dhawahir Scala">A. Dhawahir Scala</name><affiliation wicri:level="1"><nlm:affiliation>PD Biometrics, F. Hoffmann-La Roche Ltd, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>PD Biometrics, F. Hoffmann-La Roche Ltd, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Gandara, D R" sort="Gandara, D R" uniqKey="Gandara D" first="D R" last="Gandara">D R Gandara</name><affiliation wicri:level="1"><nlm:affiliation>Department of Thoracic Oncology, UC Davis Comprehensive Cancer Center, Sacramento, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Thoracic Oncology, UC Davis Comprehensive Cancer Center, Sacramento</wicri:regionArea><wicri:noRegion>Sacramento</wicri:noRegion></affiliation></author><author><name sortKey="Rittmeyer, A" sort="Rittmeyer, A" uniqKey="Rittmeyer A" first="A" last="Rittmeyer">A. Rittmeyer</name><affiliation wicri:level="1"><nlm:affiliation>Department of Thoracic Oncology, Pulmonary Clinic Immenhausen, Immenhausen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Thoracic Oncology, Pulmonary Clinic Immenhausen, Immenhausen</wicri:regionArea><wicri:noRegion>Immenhausen</wicri:noRegion><wicri:noRegion>Immenhausen</wicri:noRegion><wicri:noRegion>Immenhausen</wicri:noRegion></affiliation></author><author><name sortKey="Albert, M L" sort="Albert, M L" uniqKey="Albert M" first="M L" last="Albert">M L Albert</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Immunology, Genentech, Inc., South San Francisco, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Cancer Immunology, Genentech, Inc., South San Francisco</wicri:regionArea><wicri:noRegion>South San Francisco</wicri:noRegion></affiliation></author><author><name sortKey="Powles, T" sort="Powles, T" uniqKey="Powles T" first="T" last="Powles">T. Powles</name><affiliation wicri:level="3"><nlm:affiliation>Centre for Experimental Cancer Medicine, Barts Cancer Institute, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Centre for Experimental Cancer Medicine, Barts Cancer Institute, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Kok, M" sort="Kok, M" uniqKey="Kok M" first="M" last="Kok">M. Kok</name><affiliation wicri:level="3"><nlm:affiliation>Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Tumor Biology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Tumor Biology and Immunology, Netherlands Cancer Institute, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Herrera, F G" sort="Herrera, F G" uniqKey="Herrera F" first="F G" last="Herrera">F G Herrera</name><affiliation wicri:level="3"><nlm:affiliation>Immune Oncology Service, Lausanne University Hospital, Ludwig Institute for Cancer Research, Lausanne, Switzerland. Electronic address: Fernanda.Herrera@chuv.ch.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Immune Oncology Service, Lausanne University Hospital, Ludwig Institute for Cancer Research, Lausanne</wicri:regionArea><placeName><settlement type="city">Lausanne</settlement><region nuts="3" type="region">Canton de Vaud</region></placeName></affiliation></author></analytic><series><title level="j">Annals of oncology : official journal of the European Society for Medical Oncology</title><idno type="eISSN">1569-8041</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>Preclinical data have shown that proton pump inhibitors (PPI) can modulate the microbiome, and single-arm studies suggested that antibiotics (ATB) may decrease the efficacy of immune checkpoint inhibitors (ICI), but randomized controlled trial data are lacking. This pooled analysis evaluated the effect of ATB and PPI on outcome in patients randomized between ICI and chemotherapy.</p></div><div type="abstract" xml:lang="en"><p><b>PATIENTS AND METHODS</b></p><p>This retrospective analysis used pooled data from the phase II POPLAR (NCT01903993) and phase III OAK (NCT02008227) trials, which included 1512 patients with previously treated non-small-cell lung cancer (NSCLC) randomly assigned to receive atezolizumab (n = 757) or docetaxel (n = 755). The main objective of this analysis was to assess the impact of ATB and PPI use on overall survival (OS) and progression-free survival (PFS).</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>A total of 169 (22.3%) patients in the atezolizumab group and 202 (26.8%) in the docetaxel group received ATB, and 234 (30.9%) and 260 (34.4%), respectively, received PPI. Multivariate analysis in all patients revealed that ATB were associated with shorter OS [hazard ratio (HR) 1.20, 95% confidence interval (CI) 1.04-1.39], as was PPI (HR 1.26, 95% CI 1.10-1.44). Within the atezolizumab population, OS was significantly shorter in patients who received ATB (8.5 versus 14.1 months, HR 1.32, 95% CI 1.06-1.63, P = 0.01) or PPI (9.6 versus 14.5 months, HR 1.45, 95% CI 1.20-1.75, P = 0.0001). PPI use was associated with shorter PFS in the atezolizumab population (1.9 versus 2.8 months, HR 1.30, 95% CI 1.10-1.53, P = 0.001). There was no association between ATB and PPI use and PFS or OS within the docetaxel population.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>In this unplanned analysis from two randomized trials, data suggest that ATB or PPI use in patients with metastatic NSCLC is associated with poor outcome and may influence the efficacy of ICI.</p></div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">32115349</PMID><DateRevised><Year>2020</Year><Month>06</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1569-8041</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>04</Month></PubDate></JournalIssue><Title>Annals of oncology : official journal of the European Society for Medical Oncology</Title><ISOAbbreviation>Ann Oncol</ISOAbbreviation></Journal><ArticleTitle>Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials.</ArticleTitle><Pagination><MedlinePgn>525-531</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0923-7534(20)35927-5</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.annonc.2020.01.006</ELocationID><Abstract><AbstractText Label="BACKGROUND">Preclinical data have shown that proton pump inhibitors (PPI) can modulate the microbiome, and single-arm studies suggested that antibiotics (ATB) may decrease the efficacy of immune checkpoint inhibitors (ICI), but randomized controlled trial data are lacking. This pooled analysis evaluated the effect of ATB and PPI on outcome in patients randomized between ICI and chemotherapy.</AbstractText><AbstractText Label="PATIENTS AND METHODS">This retrospective analysis used pooled data from the phase II POPLAR (NCT01903993) and phase III OAK (NCT02008227) trials, which included 1512 patients with previously treated non-small-cell lung cancer (NSCLC) randomly assigned to receive atezolizumab (n = 757) or docetaxel (n = 755). The main objective of this analysis was to assess the impact of ATB and PPI use on overall survival (OS) and progression-free survival (PFS).</AbstractText><AbstractText Label="RESULTS">A total of 169 (22.3%) patients in the atezolizumab group and 202 (26.8%) in the docetaxel group received ATB, and 234 (30.9%) and 260 (34.4%), respectively, received PPI. Multivariate analysis in all patients revealed that ATB were associated with shorter OS [hazard ratio (HR) 1.20, 95% confidence interval (CI) 1.04-1.39], as was PPI (HR 1.26, 95% CI 1.10-1.44). Within the atezolizumab population, OS was significantly shorter in patients who received ATB (8.5 versus 14.1 months, HR 1.32, 95% CI 1.06-1.63, P = 0.01) or PPI (9.6 versus 14.5 months, HR 1.45, 95% CI 1.20-1.75, P = 0.0001). PPI use was associated with shorter PFS in the atezolizumab population (1.9 versus 2.8 months, HR 1.30, 95% CI 1.10-1.53, P = 0.001). There was no association between ATB and PPI use and PFS or OS within the docetaxel population.</AbstractText><AbstractText Label="CONCLUSION">In this unplanned analysis from two randomized trials, data suggest that ATB or PPI use in patients with metastatic NSCLC is associated with poor outcome and may influence the efficacy of ICI.</AbstractText><CopyrightInformation>Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chalabi</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: m.chalabi@nki.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cardona</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>PD Biometrics, F. Hoffmann-La Roche Ltd, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagarkar</LastName><ForeName>D R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Cancer Immunology, Genentech, Inc., South San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhawahir Scala</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>PD Biometrics, F. Hoffmann-La Roche Ltd, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gandara</LastName><ForeName>D R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Department of Thoracic Oncology, UC Davis Comprehensive Cancer Center, Sacramento, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rittmeyer</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Thoracic Oncology, Pulmonary Clinic Immenhausen, Immenhausen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albert</LastName><ForeName>M L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Cancer Immunology, Genentech, Inc., South San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Powles</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Centre for Experimental Cancer Medicine, Barts Cancer Institute, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kok</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Tumor Biology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrera</LastName><ForeName>F G</ForeName><Initials>FG</Initials><AffiliationInfo><Affiliation>Immune Oncology Service, Lausanne University Hospital, Ludwig Institute for Cancer Research, Lausanne, Switzerland. Electronic address: Fernanda.Herrera@chuv.ch.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>imCORE working group of early career investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01903993</AccessionNumber><AccessionNumber>NCT02008227</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Oncol</MedlineTA><NlmUniqueID>9007735</NlmUniqueID><ISSNLinking>0923-7534</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">antibiotics</Keyword><Keyword MajorTopicYN="Y">immune checkpoint inhibitors</Keyword><Keyword MajorTopicYN="Y">lung cancer</Keyword><Keyword MajorTopicYN="Y">microbiota</Keyword><Keyword MajorTopicYN="Y">proton pump inhibitors</Keyword></KeywordList><CoiStatement>Disclosure MC reports grants to the institute from Bristol Myers Squibb/II-ON and Roche, outside the submitted work. AC and ADS are employees of F. Hoffmann-La Roche Ltd. DRN is an employee of Genentech Inc. and reports ownership of stocks from F. Hoffmann-La Roche Ltd. DRG reports a consulting or advisory role for AstraZeneca, Celgene, CellMax Life, Genentech, Guardant Health, Lilly, Liquid Genomics, Inc., and research funding from AstraZeneca/MedImmune (Inst) and Genentech (Inst). AR reports a consultant or advisory role for AbbVie, AstraZeneca/MedImmune, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, MSD, Pfizer, and Roche/Genentech. MLA is an employee of Genentech Inc. and is now an employee of Insitro. TP reports honoraria received from Novartis, BMS, Merck, Pfizer, Roche, and AstraZeneca. MK reports funding and a speaker's fee to the institute from BMS, Roche and an unpaid advisory role for BMS, outside the submitted work. FGH reports research funding from BMS, Accuray Inc., Bioprotect, and Prostate Cancer Foundation.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>07</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>12</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>01</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32115349</ArticleId><ArticleId IdType="pii">S0923-7534(20)35927-5</ArticleId><ArticleId IdType="doi">10.1016/j.annonc.2020.01.006</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Pays-Bas</li><li>Royaume-Uni</li><li>Suisse</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Canton de Vaud</li><li>Grand Londres</li><li>Hollande-Septentrionale</li></region><settlement><li>Amsterdam</li><li>Lausanne</li><li>Londres</li></settlement></list><tree><country name="Pays-Bas"><region name="Hollande-Septentrionale"><name sortKey="Chalabi, M" sort="Chalabi, M" uniqKey="Chalabi M" first="M" last="Chalabi">M. Chalabi</name></region><name sortKey="Kok, M" sort="Kok, M" uniqKey="Kok M" first="M" last="Kok">M. Kok</name></country><country name="Suisse"><noRegion><name sortKey="Cardona, A" sort="Cardona, A" uniqKey="Cardona A" first="A" last="Cardona">A. Cardona</name></noRegion><name sortKey="Dhawahir Scala, A" sort="Dhawahir Scala, A" uniqKey="Dhawahir Scala A" first="A" last="Dhawahir Scala">A. Dhawahir Scala</name><name sortKey="Herrera, F G" sort="Herrera, F G" uniqKey="Herrera F" first="F G" last="Herrera">F G Herrera</name></country><country name="États-Unis"><noRegion><name sortKey="Nagarkar, D R" sort="Nagarkar, D R" uniqKey="Nagarkar D" first="D R" last="Nagarkar">D R Nagarkar</name></noRegion><name sortKey="Albert, M L" sort="Albert, M L" uniqKey="Albert M" first="M L" last="Albert">M L Albert</name><name sortKey="Gandara, D R" sort="Gandara, D R" uniqKey="Gandara D" first="D R" last="Gandara">D R Gandara</name></country><country name="Allemagne"><noRegion><name sortKey="Rittmeyer, A" sort="Rittmeyer, A" uniqKey="Rittmeyer A" first="A" last="Rittmeyer">A. Rittmeyer</name></noRegion></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Powles, T" sort="Powles, T" uniqKey="Powles T" first="T" last="Powles">T. Powles</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PoplarV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000439 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000439 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= PoplarV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32115349
|texte= Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32115349" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PoplarV1
| This area was generated with Dilib version V0.6.37. |  |